Asieris aims to become a specialty pharmaceutical company in urology and urogenital cancers. Our leading clinical candidates APL-1202 and APL-1301 are the first oral drugs in the world for the treatment of non-muscular-invasive bladder cancer, (NMIBC) and are expected to shift the current treatment paradigm for NMIBC.
In addition to our breakthrough drugs advanced to clinical development, we possess a strong team of experts in discovery and clinical R&D to support molecular optimization and to advance our clinical programs in China. We will continue to develop high quality, novel compounds internally, and to further enrich our product portfolio through in-licensing or alliance.
Besides clinical development, we have also established proprietary R&D platforms，focusing on a novel MOA through small molecule immunomodulation for anticancer drug discovery. We are looking forward to a productive partnership to advance our R&D program.
We hope to collaborate with the world’s leading research institutions in the areas below, and are confident that you will find Asieris your best partner.